This guideline assesses the evidence regarding the maternal and fetal risks of varicella zoster virus (VZV) infection in pregnancy and whether these complications can be prevented or modified by the administration of varicella zoster immune globulin (VZIG) or by treatment with aciclovir.
This is the fourth edition of this guideline, originally published in 1997 and reviewed in 2001 and 2007 under the same title.
Varicella, the primary infection with varicella-zoster virus (VZV; human herpes virus 3), in pregnancy may cause maternal mortality or serious morbidity. It may also cause fetal varicella syndrome (FVS) and varicella infection of the newborn, which includes congenital varicella syndrome (CVS) and neonatal varicella.
This guideline addresses the role of varicella vaccination in susceptible women of reproductive age. The guideline also assesses the evidence regarding the maternal and fetal risks of VZV infection in pregnancy and whether or not these complications can be prevented or modified beneficially by the administration of varicella-zoster immunoglobulin (VZIG) or by treatment of infected individuals with aciclovir.
This information should guide the prudent use of VZIG, which is manufactured from the plasma of human blood donors and hence is a limited and expensive resource.
The management of neonates is outside the scope of this guideline. Guidance on neonatal exposure and disease is available on the www.gov.uk website.